



**Attn: Trading and Market Making / Legal and Compliance / Operations / Systems**  
**UNIFORM PRACTICE ADVISORY (UPC #30-19) 9/25/2019**  
**Aegerion Pharmaceuticals, Inc. 2% Senior Unsecured Convertible Notes Due**  
**08/15/2019**

Notice has been received that the above Company's First Amended Joint Chapter 11 Plan became effective on 9/24/2019. On the effective Date, except to the extent that a holder of an Allowed Other General Unsecured Claim agrees to less favorable treatment, each holder of an Allowed Other General Unsecured Claim shall receive, on the applicable Distribution Date and in full and final satisfaction, settlement and release of such Allowed Other General Unsecured Claim, its Pro Rata Share of: (i) New Convertible Notes in the principal amount of \$125,000,000 less the portion of New Convertible Notes distributed to (x) holders of DIP Claims (to the extent the DIP Claims are not repaid in full in Cash and receive a distribution of New Convertible Notes pursuant to Section 3.1 hereof), and (y) the holders of Roll Up Loan Claims pursuant to Section 5.3(a)(ii) hereof; and (ii) the Class 6B New Common Stock Distribution. Please consult the company's bankruptcy filings for thorough details.<sup>1</sup>

Issuer of Original Securities	Description of Original Securities	CUSIP of Original Securities	Rate of New 5% Convertible Notes per \$1,000 of PA	Rate of New ADR Per \$1,000 of PA	Rate of New Escrow (CUSIP) per \$1,000 of PA
Aegerion Pharmaceuticals, Inc.	2% Senior Unsecured Convertible Notes	00767EAB8	332.59267486	46.29197878	1,000.00

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Operations- 1-866-776-0800.

<sup>1</sup> See e.g., *In re: Aegerion Pharmaceuticals, Inc., et al.*, Debtor. Chapter 11 Case No. 19-11632 (MG) Modified First Amended Joint Chapter 11 Plan.